Project description
A comprehensive cancer therapy targets tumour cells throughout the tumour molecular network
Cancer is a group of diseases characterised by the uncontrolled growth of abnormal cells that can invade nearby tissues and spread to other parts of the body. More than 18 million cases of cancer were diagnosed in 2020 alone, accounting for nearly 10 million deaths. Although significant advances have been made in detecting and treating cancer, the vast complexity of tumours makes treatment challenging. Pattern BioSciences, an innovative biotechnology start-up, is developing disruptive gene therapies that target tumour cells throughout the tumour molecular network. The EU-funded CancerQR project is supporting a feasibility study that could lead to partnerships with established pharma and biotech players.
Objective
"Pattern BioSciences is an ETH Zurich Spin-Off and an innovative biotechnology start up that proposes a paradigm shifting
approach towards tailored and customizable cancer therapies. The company is commercializing the disruptive ""Network
against Network"" approach to cancer therapies, which takes into account tumor complexity and probes and targets tumor
cells at multiple points of tumor molecular network. The therapies will be more efficacious, less toxic and less prone to drug
resistance compared to the state of the art treatments. Building on large IP portfolio and extensive expertise and know-how
of its founders, the company proposes this feasibility study to assess the commercialization potential of its offering via
intensive partner search, stakeholder alignment, freedom to operate analysis, and formulating IPR and knowledge
management strategy. With company's current Minimal Viable Product (MVP) at TRL 6, interaction with prospective parters during this
feasibility study will define the set of Customizable Therapeutic Prototypes (CTPs) at TRL 9, conducive to entering into partnership deals. Delivering CTPs in the Phase II of the innovation action will enable the company to enter into large scale, long term partnership
agreements with established players in Pharma and Biotech industries and execute a European-wide growth and expansion
plan, creating multiple jobs and strengthening Europe as an innovative Biotechnology hub."
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences clinical medicine oncology
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4058 BASEL
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.